1. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. Int J Cancer;G Gao,2012
2. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med;S Kobayashi,2005
3. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research;IJ Dahabreh,2010
4. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med;TS Mok,2009
5. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol;HL West,2006